![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C10H11N4O7P |
Molar mass | 330.193 g·mol−1 |
3D model (JSmol) | |
| |
|
Becampanel (INN) (code name AMP397) is a quinoxalinedione derivative drug which acts as a competitive antagonist of the AMPA receptor (IC50 = 11 nM).[1][2][3][4] It was investigated as an anticonvulsant for the treatment of epilepsybyNovartis, and was also looked at as a potential treatment for neuropathic pain and cerebral ischemia, but never completed clinical trials.[1][2][3][5]
| |
---|---|
AMPARTooltip α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor |
|
KARTooltip Kainate receptor |
|
NMDARTooltip N-Methyl-D-aspartate receptor |
|
|
![]() | This anticonvulsant-related article is a stub. You can help Wikipedia by expanding it. |